All
Copanlisib Granted Priority Review for Lymphoma
May 17th 2017Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.
Lessons From the NICU: Caring for Cancer Caregivers When They Need It Most
May 17th 2017Knowing that parents of critically ill infants in the neonatal intensive care unit (NICU) receive a specific set of nursing-based supports, a team of nurses at UC Irvine Health in Huntington Beach, California, set out to find out whether lessons from the NICU can be applied in the inpatient oncology setting and developed an evidence-based protocol modeled on the NICU experience.
New Rituxan Results as FDA Decision Nears for Lymphoma
May 17th 2017There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting, according to results from the phase 3 SABRINA trial that were published in The Lancet Haematology.